RaySight Medical Named to 2024 Top 100 Emerging Enterprises in MedTech and Top 10 in Medical Imaging Innovation; CEO Dr. Lingxiao Zheng Honored as Emerging Entrepreneur

Dec 18, 2024 12:02 CST Updated 12:02

RaysightMed

Medical Imaging Product Developer

Recently, the 2024 Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition grandly opened at the Shenzhen Convention and Exhibition Center (Futian). At the opening ceremony, the National High-Performance Medical Device Innovation CenterOfficial Release2024 Annual Innovation Ecosystem Insight Assessment of the Medical Device Industry。

RaysightMedRaysightMed Ranks High with Outstanding Innovation Strength“2024Innovation Index of Emerging Enterprises in the Medical Device IndustryTOP100”With "2024Innovation Index in the Medical Imaging Field of the Medical Device IndustryTOP10”。

Founder andCEOZheng LingxiaoDr. RaysightMed has demonstrated exceptional leadership and forward-thinking innovation.New Horizons, Awarded“2024"Rising Entrepreneur in the Medical Device Industry" Title

RaysightMed Team Showcases New Generation AngioQFA Product at the Venue

AngioQFA 100, Coronary Functional Measurement System, achieves efficient, non-invasive, and comprehensive coronary blood supply assessment for the first time through the advanced integration of AI and fluid dynamics technology based on coronary angiography images. It provides FFR and IMR measurements for coronary arteries and microcirculation, offering precise guidance throughout the PCI process. Additionally, it has the ability to evaluate plaque stability and perform surgical planning, delivering multi-dimensional precision information that highlights its excellence and leadership in the field of cardiovascular diagnosis and treatment.

Shenzhen Raysightmed Co, Ltd. was established in December 2017. It is a high-tech enterprise in China that focuses on artificial intelligence for cardiovascular and cerebrovascular diseases and precision diagnosis and treatment with surgical robots.

RaysightMed independently developed and launched a series of products including non-invasive functional diagnosis, surgical planning navigation, and vascular interventional surgical robots, committed to providing clinical AI + surgical robot integrated hardware and software intelligent diagnosis and treatment platforms for coronary arteries. RaysightMed holds 9 NMPA certificates and 1 EU CE certificate, with over 200 patents applied for and authorized.

The company won the 2021 China ArtificialTop 10 in Intelligent Medical Imaging, Top 10 in China's Innovative Medical Devices 2022, First Prize in the 2022 China Industry-University-Research Collaboration Innovation Achievement Awards, Third Prize in the 2022 China Innovation and Entrepreneurship Competition National Finals, and the 2023 Shenzhen Postdoctoral Innovation Practice Base, among other honors. Leading national key R&D projects, the Peacock Team, and special projects from the Shenzhen Medical Academy.RaysightMed has enormous development potential, strong ongoing operational capabilities, and its products have entered over 800 tertiary hospitals across China.Completed 5 rounds of financing led by Matrix Partners, Tencent, and SDIC Venture Capital successively, developing into a leading potential unicorn enterprise in the same track.